339P - Chronic myeloid leukemia: diagnosis, management and treatment options in Moldova

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Leukaemia
Presenter Vasile Musteata
Citation Annals of Oncology (2016) 27 (suppl_9): ix104-ix111. 10.1093/annonc/mdw586
Authors V. Musteata
  • Oncology, Hematology And Radiotherapy Department, State University of Medicine and Pharmacy "N. Testemitanu", Institute of Oncology, 2025 - Chisinau/MD



We consider the management of chronic myeloid leukemia (CML) challenging due to untimely diagnosis and mostly reserved prognosis.


The cohort study enrolled 125 CML patients (pts), followed up at the Institute of Oncology. The male/female ratio was 1.4:1. The age ranged between 19 – 81 years. Chronic phase was diagnosed in 113 (90.4±2.32%) cases, accelerated and acute phases – in 12 (9.6±2.02%). Ph-positive marrow cells exceeded 75% in 72.7% of pts. 81 (64.8%) pts were approved for GIPAP, 4 (4.0%) – for NOAT program. Imatinib was used as a front-line therapy in 19 (22.1%) cases, and in 67 (77.9%) cases of the relapse or resistance to non-TKIs therapy. Of 21 (24.4%) imatinib-resistant pts, 10 (47.6%) received dasatinib therapy.


The CML prevalence increased (2004 – 2,11%ооо, 2010 – 3,40%ооо, 2014 – 4,16%ооо). The mostly affected age group was 40 – 49 years (27.4±4.89%). 59.6±4.99% of pts were exposed to insolation during their activities (correlation coefficient 0.479). Complete hematologic response (CHR) rate was 85.1% under TKIs therapy and outruned (p 


CML occurs commonly in a workable male population. The insolation may be suggested as a favoring factor in pathogenesis of CML. The pts managed with TKIs achieved much higher CHR and survival, as compared to pts treated with non-TKIs therapy. The TKIs supply via GIPAP and NOAT improves the outcomes in CML pts, leading to the recovery and restoration of the ability to work.

Clinical trial indentification

The Council approval number 8/6

Legal entity responsible for the study

State University of Medicine and Pharmacy, Institute of Oncology


Axios International, Novartis


All authors have declared no conflicts of interest.